ASCO24 Updates: Dr. Anastasios Kyriazoglou on Pathologic Complete Response in Sarcomas

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Dr. Anastasios Kyriazoglou from University of Athens, shared insights on ‘Pathologic complete response in patients with localized soft tissue sarcoma treated with neoadjuvant therapy and its correlation with clinical outcomes: A systematic review.‘

My name is Anastasios Kyriazoglou. I am a medical oncologist from the University of Athens at the Attikon University Hospital. We have conducted a systematic review regarding the impact of pathologic complete response in localized soft tissue sarcomas.

We have analyzed 23 papers and our results suggest that there is a positive impact of pathologic complete response and five-year disease-specific survival and overall survival. However, we still have to define well what exactly pathologic complete response is in soft tissue sarcomas and of course we have to set up prospective clinical trials with pathologic complete response being one of the endpoints of these trials.

More videos and content from ASCO 2024 on OncoDaily.